Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: (301) 983-0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

BreezyAngel21424 Aug. 20 at 1:29 AM

$IGC Golden Cross....history shows us that IGC will make a substantial run up at this point, Im saying likely in the 75-80cent range very soon and with any news or PR, we could easily run above $2. I loaded up today when I saw the Golden Cross. Very Bullish at this point.

0 · Reply

Bulltrader988 Aug. 19 at 1:28 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-reports-first-quarter-fiscal-2026-financial-results-hnz39m0ms8lw.html

0 · Reply

dolfin20th Aug. 19 at 5:19 AM

$IGC

0 · Reply

TheXten Aug. 19 at 4:38 AM

$IGC

0 · Reply

QuantumWizard Aug. 18 at 8:27 PM

$IGC Ok, I don't really post anything about this stock, but I feel i must mention this to all the Longs here. Historically whenever this stock approaches or passes it's Golden Cross area, it typically has always 4x or 5x....I'll just leave it at that.

2 · Reply

1RayRay Aug. 18 at 7:21 PM

$IGC

0 · Reply

transamlover Aug. 18 at 5:48 PM

$IGC

0 · Reply

angel6 Aug. 18 at 3:42 PM

$IGC did they announce their E/R ?

0 · Reply

TheXten Aug. 18 at 11:59 AM

$IGC

0 · Reply

Golferhack12 Aug. 17 at 6:55 PM

$IGC I've never seen a stock that literally doesn't move it had that one good spike a few weeks ago which came out of nowhere but has not moved out of this range for years

1 · Reply

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 8 days ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 15 days ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 5 weeks ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 7 weeks ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 2 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 6 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 7 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 7 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 8 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 10 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Oct 17, 2024, 8:30 AM EDT - 10 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 3, 2024, 9:00 AM EDT - 11 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Sep 18, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 4, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 8, 2024, 9:30 PM EDT - 1 year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

Jul 18, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jun 25, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 10, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

May 28, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 9, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Adds Advisor in Artificial Intelligence

Mar 26, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 20, 2024, 11:00 AM EDT - 1 year ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 7:00 AM EDT - 1 year ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 12, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

BreezyAngel21424 Aug. 20 at 1:29 AM

0 · Reply

Bulltrader988 Aug. 19 at 1:28 PM

$IGC 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-reports-first-quarter-fiscal-2026-financial-results-hnz39m0ms8lw.html

0 · Reply

dolfin20th Aug. 19 at 5:19 AM

$IGC

0 · Reply

TheXten Aug. 19 at 4:38 AM

$IGC

0 · Reply

QuantumWizard Aug. 18 at 8:27 PM

2 · Reply

1RayRay Aug. 18 at 7:21 PM

$IGC

0 · Reply

transamlover Aug. 18 at 5:48 PM

$IGC

0 · Reply

angel6 Aug. 18 at 3:42 PM

$IGC did they announce their E/R ?

0 · Reply

TheXten Aug. 18 at 11:59 AM

$IGC

0 · Reply

Golferhack12 Aug. 17 at 6:55 PM

$IGC I've never seen a stock that literally doesn't move it had that one good spike a few weeks ago which came out of nowhere but has not moved out of this range for years

1 · Reply

UCIdidmyDD Aug. 17 at 6:35 PM

$IGC long 65000 common

0 · Reply

Tom678 Aug. 15 at 12:46 PM

$IGC $1 very soon

0 · Reply

BigSqueezeComing Aug. 15 at 10:34 AM

$IGC top gainers today

0 · Reply

oii Aug. 15 at 9:54 AM

$IGC lets shoot up

0 · Reply

Tom678 Aug. 15 at 1:33 AM

$IGC $MSOX $TLRY $VFF IGC is a gem 💎

0 · Reply

UCIdidmyDD Aug. 15 at 1:32 AM

$MSOX $VFF $TLRY $IGC added ycbd today . keeper

1 · Reply

RAGC Aug. 14 at 8:28 PM

$IGC news 👇 https://www.sec.gov/Archives/edgar/data/1326205/000118518525000997/igc10q063025.htm

0 · Reply

Bulltrader988 Aug. 14 at 8:22 PM

$IGC 10Q filled 👃👀 https://www.sec.gov/ix?doc=/Archives/edgar/data/1326205/000118518525000997/igc10q063025.htm

0 · Reply

hardrock2112 Aug. 14 at 8:15 PM

$IGC nice.

0 · Reply

Mack43 Aug. 14 at 2:43 PM

$IGC slowest gains ever!!!

0 · Reply

UCIdidmyDD Aug. 14 at 6:30 AM

$MSOS what i do know is that trump fights like a rabid dog for his priorities. no other president goes to the legths to secure political victory than this cat. and everything shows hes for medical ganj. i stick with medical $IGC an old presidents bf. $MSOX for those outrageously cheap dispensaries, and $VFF and $TLRY for boots on the ground and fresh green in the air .

1 · Reply

Llamasinthebahamas Aug. 14 at 2:05 AM

$IGC did this really shoot up to $13 back in 2018?

0 · Reply

Market Cap	34.52M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	359,300
Avg Vol	3,283,140
Day's Range	N/A - N/A
Shares Out	90.81M
Stochastic %K	71%
Beta	1.48
Analysts	Sell
Price Target	$3.88